We recently compiled a list of the 11 AI News and Ratings You Shouldn’t Miss. In this article, we are going to take a look at ...

We recently published a list of 9 Trending AI News Updates on Wall Street’s Radar. In this article, we are going to take a ...

TD Cowen analyst Bryan Bergin upgraded Genpact (G) to Buy from Hold with a price target of $60, up from $45. The company’s turnaround traction ...

TD Cowen reaffirmed their buy rating on shares of Tempus AI (NASDAQ:TEM – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. TD Cowen currently has a $74.00 price ...

TD Cowen began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research report released on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a ...

TD Cowen analyst Jared Levine raised the firm’s price target on Paylocity (PCTY) to $242 from $228 and keeps a Buy rating on the shares. The ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

TD Cowen was established in 1918 as a bond trading firm and quickly expanded into clearing and execution services. By the 1970s, it had carved a niche in railroad bonds and grown a solid research ...

Investing.com -- TD Cowen analysts view Sen. Dan Sullivan’s proposed missile defense legislation as a long-term catalyst for major U.S. defense contractors, with Lockheed Martin (NYSE ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...